Search

The essentials of the news: Gilead, Sandoz, Innate Pharma and Dassault Systèmes

Translated title. Original: L’essentiel de l’actualité : Gilead, Sandoz, Innate Pharma et Dassault Systèmes

The article outlines four industry movements—Gilead's Yeytuo with EU authorization but with access caveats, Sandoz's role in biosimilars to expand options and control costs, Innate Pharma's biotechnology partnership with Sobi, and Dassault Systèmes' digital tools via ArisGlobal acquisition—highlighting pricing, access, and real-world patient impact as key concerns while cautioning that approvals and partnerships do not guarantee immediate patient benefits.

Ebrard announces target to quadruple pharmaceutical ingredient production in five years

Translated title. Original: Ebrard anuncia meta para cuadruplicar producción de insumos farmacéuticos en cinco años

Mexico plans to quadruple its domestic production of pharmaceutical ingredients and petrochemicals over five years to cut import dependence, backed by 245 million USD in investments including Avant Santé expansion and a Tecnológico de Monterrey center. The project links hospitals, universities, and firms to develop new treatments and technologies, with a projected economic impact of at least 30 billion MXN between 2027 and 2030.

Conference "Bioadditives Market Today 2026" – business events | Retail.ru

Translated title. Original: Конференция «Рынок БАД сегодня 2026» – деловые события | Retail.ru

A two-day conference in Moscow gathers pharma and BaD industry leaders to discuss regulatory changes, marketing, omnichannel retail, and costs of compliance, with sessions on registration to prescriptions, GMP, and networking activities.

Silicon Valley Promises AI Will Cure Disease. Drugmaker CEOs Aren’t Buying It.

No drug designed by artificial intelligence has won FDA clearance, and pharma leaders say biology is the obstacle.

MHRA to Strengthen Patient Voice in Medicines Regulation - Pharmacy Business

The MHRA’s 2026–2030 plan sets out steps to involve patients earlier and more widely in medicines and medical device regulation. Patient input is intended to inform safety reviews, regulatory decisions and patient information, with progress overseen by the agency’s engagement committee.

OpenAI vs Google DeepMind: How the AI drug discovery race is shaping up

Two AI firms race to shape drug discovery: DeepMind's Isomorphic Labs advances molecule design from AlphaFold, backed by $2.1B, while OpenAI buys Orchestra Bio to oversee drug trials and analysis. The path to clinical use faces scientific, regulatory, and trust hurdles, with India a key regional factor shaping adoption and risk.

Anthropic bets on life sciences for its IPO | AI Briefing

Translated title. Original: Anthropic mise sur les sciences de la vie pour son IPO | Brief IA

Anthropic aims to pivot its IPO strategy around life sciences, leveraging AI to accelerate biomedical R&D, with significant pharma partnerships, a new biology lab, and strategic hires; the firm notes no AI-designed drug has FDA approval, while signaling strong optimism and industry interest, including investments from Lilly and other top health companies.

AI that delves into pharmaceuticals and medical field, will it achieve treatment outcomes beyond development and diagnosis - Safe Times

Translated title. Original: 제약·의료 파고든 AI, 개발·진단 넘어 치료 성과 낼까 - 세이프타임즈

AI is accelerating in drug development and medical diagnostics, but its ability to improve patient survival and clinical trial success remains under verification; partnerships and investments rise as companies apply AI to target discovery, patient selection, and diagnostic tools, with timelines targeting preclinical and later clinical milestones.

LLMs favor brand-name drugs that are more visible online, study reports impact on costs

Translated title. Original: LLM favoriscono farmaci di marca più visibili online, studio segnala impatto sui costi

A study using five large language models finds they disproportionately recommend brand-name, highly visible drugs, potentially raising US drug acquisition costs by about $55.6 million annually in simulated scenarios; authors call for human oversight and reliable drug information sources to mitigate cost distortions.

Isomorphic Labs is negotiating according to Bloomberg about 5 billion dollars at a 50 billion valuation

Translated title. Original: Isomorphic Labs verhandelt laut Bloomberg über 5 Milliarden Dollar bei 50 Milliarden Bewertung

Isomorphic Labs, a Google DeepMind spin-out focused on AI-designed drugs, is reportedly negotiating a new funding round of about $5 billion at a roughly $50 billion valuation. The talks follow rapid funding activity, including a $2.1 billion Series B and prior rounds, with partnerships from Lilly, Novartis, and J&J. The company aims to shorten drug development using its IsoDDE engine, but observers caution that investors are valuing the platform rather than an approved drug.